IBRX ImmunityBio, Inc.
Healthcare$7.92+9.70%ClosedMarket Cap: $8.30B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-8.52
P/S
53.64
EV/EBITDA
-44.23
DCF Value
$-22.44
FCF Yield
-4.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
93.8%
Operating Margin
-185.4%
Net Margin
-606.2%
ROE
138.7%
ROA
-132.2%
ROIC
-44.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $44.2M | 99.5% | $-69.8M | $-632.8M | $— | — |
| Q4 null | $38.3M | 88.9% | $-64.7M | $-61.9M | $— | — |
| FY null | $113.3M | 99.3% | $-256.0M | $-351.4M | $— | — |
| Q3 null | $32.1M | 87.1% | $-55.6M | $-67.3M | $— | — |
| Q2 null | $26.4M | 99.5% | $-71.3M | $-92.6M | $— | — |
| Q1 null | $16.5M | 99.6% | $-64.4M | $-129.6M | $— | — |
| Q4 null | $7.6M | 100.0% | $-69.4M | $-59.2M | $— | — |
| FY null | $14.7M | 100.0% | $-344.2M | $-413.6M | $— | — |
| Q3 null | $6.1M | 100.0% | $-80.3M | $-85.7M | $— | — |
| Q2 null | $1.0M | 100.0% | $-99.3M | $-134.6M | $— | — |
| Q1 null | $40.0K | 100.0% | $-95.2M | $-134.1M | $— | — |
| Q4 2023 | $139.0K | 100.0% | $-85.4M | $-233.4M | $-0.40 | — |